KR102510832B1 - P2y12 수용체 안타고니스트의 피하 투여 - Google Patents

P2y12 수용체 안타고니스트의 피하 투여 Download PDF

Info

Publication number
KR102510832B1
KR102510832B1 KR1020197029753A KR20197029753A KR102510832B1 KR 102510832 B1 KR102510832 B1 KR 102510832B1 KR 1020197029753 A KR1020197029753 A KR 1020197029753A KR 20197029753 A KR20197029753 A KR 20197029753A KR 102510832 B1 KR102510832 B1 KR 102510832B1
Authority
KR
South Korea
Prior art keywords
receptor antagonist
pharmaceutically acceptable
acceptable salt
administered
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197029753A
Other languages
English (en)
Korean (ko)
Other versions
KR20190124297A (ko
Inventor
마르띤 바우만
마르쿠스 크람베르크
마르쿠스 라이
마르쿠스 리데러
세바스띠앙 루
Original Assignee
이도르시아 파마슈티컬스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이도르시아 파마슈티컬스 리미티드 filed Critical 이도르시아 파마슈티컬스 리미티드
Publication of KR20190124297A publication Critical patent/KR20190124297A/ko
Application granted granted Critical
Publication of KR102510832B1 publication Critical patent/KR102510832B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020197029753A 2017-03-15 2018-03-14 P2y12 수용체 안타고니스트의 피하 투여 Active KR102510832B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2017/056175 2017-03-15
EP2017056175 2017-03-15
PCT/EP2018/056372 WO2018167139A1 (en) 2017-03-15 2018-03-14 Subcutaneous administration of a p2y12 receptor antagonist

Publications (2)

Publication Number Publication Date
KR20190124297A KR20190124297A (ko) 2019-11-04
KR102510832B1 true KR102510832B1 (ko) 2023-03-15

Family

ID=61899166

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197029753A Active KR102510832B1 (ko) 2017-03-15 2018-03-14 P2y12 수용체 안타고니스트의 피하 투여

Country Status (18)

Country Link
US (1) US11179390B2 (https=)
EP (1) EP3595666A1 (https=)
JP (3) JP7580918B2 (https=)
KR (1) KR102510832B1 (https=)
CN (1) CN110381947A (https=)
AU (1) AU2018234056B2 (https=)
BR (1) BR112019014567A2 (https=)
CL (1) CL2019002318A1 (https=)
EA (1) EA201992123A1 (https=)
IL (1) IL269286B2 (https=)
MA (1) MA49887A (https=)
MX (1) MX393334B (https=)
MY (1) MY205605A (https=)
PH (1) PH12019502111A1 (https=)
SG (1) SG11201908128YA (https=)
TW (1) TWI765002B (https=)
UA (1) UA125531C2 (https=)
WO (1) WO2018167139A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3515924B1 (en) 2016-09-22 2021-12-15 Idorsia Pharmaceuticals Ltd Crystalline forms
MA49887A (fr) * 2017-03-15 2020-06-24 Idorsia Pharmaceuticals Ltd Administration sous-cutanée d'un antagoniste du récepteur p2y12
SMT202600015T1 (it) 2020-07-15 2026-03-09 Viatris Asia Pacific Pte Ltd Composizione farmaceutica acquosa comprendente un antagonista del recettore p2y12
MX2024000653A (es) 2021-07-13 2024-01-31 Idorsia Pharmaceuticals Ltd Un proceso para la sintesis de ester de butilo de acido 4-((r)-2-{[6-((s)-3-metoxi-pirrolidin-1-il)-2-fenil-pirimidin-4-c arbonil]-amino}-3-fosfono-propionil)-piperazin-1-carboxilico.
US20250197904A1 (en) 2022-03-14 2025-06-19 Viatris Asia Pacific Pte. Ltd. A process for the synthesis of ( r)-2-(( tert-butoxycarbonyl)amino)-3-(diethoxyphosphoryl)propanoic acid or of phosphonate derivatives thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011137459A1 (en) * 2010-04-30 2011-11-03 Portola Pharmaceuticals, Inc. Dosage forms of elinogrel and methods of injectable administration thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870035A (en) 1970-07-17 1975-03-11 Survival Technology Method and apparatus for self-administering pre-hospital phase treatment of coronary prone individuals in the early minutes or hours after the onset of heart attack symptoms
US4004577A (en) 1972-12-04 1977-01-25 Survival Technology, Inc. Method of treating heart attack patients prior to the establishment of qualified direct contact personal care
JPS5373586A (en) 1976-12-09 1978-06-30 Mitsubishi Chem Ind Ltd New penicillin derivatives
US4795433A (en) 1985-05-20 1989-01-03 Survival Technology, Inc. Automatic injector for emergency treatment
US4658830A (en) 1984-08-08 1987-04-21 Survival Technology, Inc. Method and apparatus for initiating reperfusion treatment by an unattended individual undergoing heart attack symptoms
US5078680A (en) 1984-08-08 1992-01-07 Survival Technology, Inc. Automatic injector for emergency treatment
GR861289B (en) 1985-05-20 1986-09-16 Survival Technology Injection method and apparatus with electrical blood absorbing stimulation
CA2020437A1 (en) 1989-07-05 1991-01-06 Yoshihide Fuse Cinnamamide derivative
JP2003502314A (ja) 1999-06-14 2003-01-21 イーライ・リリー・アンド・カンパニー 化合物
US6861424B2 (en) 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
DE60333866D1 (de) 2002-12-11 2010-09-30 Bayer Schering Pharma Ag 2-aminocarbonlyl-chinolin-verbindungen als adenosin diphosphat plättchenrezeptor antagonisten
ATE481103T1 (de) 2003-04-09 2010-10-15 Wyeth Llc Derivate von 2-(8,9-dioxo-2,6- diazabicyclo(5.2.0)non-1(7)-en-2- yl)alkylphosphonsäure und deren verwendung als n- methyl-d-aspartat- (nmda-) rezeptorantagonisten
AU2003249865A1 (en) * 2003-06-24 2005-01-21 Actelion Pharmaceuticals Ltd Pyrazolidinedione derivatives and their use as platelet aggregation inhibitors
TW200640877A (en) 2005-04-28 2006-12-01 Actelion Pharmaceuticals Ltd Pyrimidine derivatives
AU2006305538B2 (en) 2005-10-21 2012-06-28 Idorsia Pharmaceuticals Ltd Piperazine derivatives as antimalarial agents
CL2007002920A1 (es) 2006-10-13 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
CL2007003038A1 (es) 2006-10-25 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos.
JP4785881B2 (ja) 2007-02-27 2011-10-05 大塚製薬株式会社 医薬
MX2009011089A (es) 2007-04-23 2009-10-30 Sanofi Aventis Derivados de quinolina-carboxamida en calidad de antagonistas de p2y12.
CA2686203A1 (en) 2007-05-02 2008-11-13 Portola Pharmaceuticals, Inc. Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor
EP2225253B1 (en) 2007-11-29 2012-06-27 Actelion Pharmaceuticals Ltd. Phosphonic acid derivates and their use as p2y12 receptor antagonists
EP2238127B1 (en) 2007-12-26 2012-08-15 Sanofi Pyrazole-carboxamide derivatives as p2y12 antagonists
EP2238128B1 (en) 2007-12-26 2012-08-22 Sanofi Heterocyclic pyrazole-carboxamides as p2y12 antagonists
AR071652A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2- fenil-piridina substituidos
AR071653A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2-fenil-4-ciclopropil-pirimidina
MA33260B1 (fr) 2009-04-08 2012-05-02 Actelion Pharmaceuticals Ltd 6-(3-azabicyclo[3.1.0.]hex-3-yl)-2-phenylpyrimidines
CA2756654C (en) 2009-04-22 2017-08-22 Actelion Pharmaceuticals Ltd Thiazole derivatives and their use as p2y12 receptor antagonists
WO2011160768A1 (en) 2010-06-23 2011-12-29 Stefan Kralev Medical device for self-administration of patients with acute coronary events
EP3515924B1 (en) 2016-09-22 2021-12-15 Idorsia Pharmaceuticals Ltd Crystalline forms
MA49887A (fr) * 2017-03-15 2020-06-24 Idorsia Pharmaceuticals Ltd Administration sous-cutanée d'un antagoniste du récepteur p2y12

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011137459A1 (en) * 2010-04-30 2011-11-03 Portola Pharmaceuticals, Inc. Dosage forms of elinogrel and methods of injectable administration thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of Medicinal Chemistry. Vol.58, No.23, pp.9133-9153 (2015.)*

Also Published As

Publication number Publication date
AU2018234056A1 (en) 2019-10-31
TW201840323A (zh) 2018-11-16
SG11201908128YA (en) 2019-10-30
EP3595666A1 (en) 2020-01-22
EA201992123A1 (ru) 2020-02-25
IL269286B1 (en) 2023-04-01
JP2020510043A (ja) 2020-04-02
BR112019014567A2 (pt) 2020-02-18
US11179390B2 (en) 2021-11-23
TWI765002B (zh) 2022-05-21
PH12019502111A1 (en) 2020-03-16
CN110381947A (zh) 2019-10-25
WO2018167139A1 (en) 2018-09-20
IL269286B2 (en) 2023-08-01
US20200129510A1 (en) 2020-04-30
IL269286A (en) 2019-11-28
MA49887A (fr) 2020-06-24
KR20190124297A (ko) 2019-11-04
CL2019002318A1 (es) 2020-01-10
UA125531C2 (uk) 2022-04-13
JP2023052576A (ja) 2023-04-11
AU2018234056B2 (en) 2023-05-25
MY205605A (en) 2024-10-29
MX393334B (es) 2025-03-24
JP7580918B2 (ja) 2024-11-12
JP2025060907A (ja) 2025-04-10
CA3050831A1 (en) 2018-09-20
NZ757938A (en) 2024-07-05
MX2019009559A (es) 2019-10-15

Similar Documents

Publication Publication Date Title
KR102510832B1 (ko) P2y12 수용체 안타고니스트의 피하 투여
US20180344682A1 (en) Compositions and methods for treating ischemic stroke
KR20180032578A (ko) 염증 및 암 질환의 치료를 위한 클로로퀸 및 클레미졸 화합물의 용도
US20180078497A1 (en) Stable Parenteral DNJ Compositions
AU2012254057B2 (en) Use of A2B adenosine receptor antagonists for treating heart failure and arrhythmia in post-myocardial infarction patients
KR20110013352A (ko) 심혈관 질환을 치료하기 위한 라놀라진의 용도
KR20100038322A (ko) 당뇨병 치료 방법
CA3050831C (en) Subcutaneous administration of a p2y12 receptor antagonist
KR102934168B1 (ko) P2y12 수용체 안타고니스트를 포함하는 수성 약제학적 조성물
EA042138B1 (ru) Подкожное введение антагониста p2y12 рецептора
KR20090024248A (ko) Ｃｘｃｒ2의 선택적 길항제 또는 ｃｘｃｒ1과 ｃｘｃｒ2 둘다의 선택적 길항제의 약제학적 제형 및 조성물, 및 염증성 질환을 치료하기 위한 이의 사용방법
US11116741B2 (en) Method for the treatment of valvular heart disease comprising administering a composition comprising sarpogrelate
KR102741835B1 (ko) 등검은말벌독에 함유된 세로토닌의 안정성을 유지하기 위한 조성물

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4